Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleeding
2006

Ineffective Use of Recombinant Activated Factor VII in Gastrointestinal Bleeding After Bone Marrow Transplantation

Sample size: 1 publication Evidence: low

Author Information

Author(s): Phillip Eller, Christoph Pechlaner, Christian Wiedermann

Primary Institution: Medical University of Innsbruck

Hypothesis

Is recombinant activated factor VII an effective treatment for severe gastrointestinal bleeding in non-haemophilic patients after bone marrow transplantation?

Conclusion

The case suggests that recombinant activated factor VII is not effective for severe gastrointestinal bleeding after bone marrow transplantation.

Supporting Evidence

  • Recombinant activated factor VII is effective in hemophilia but lacks evidence for non-haemophilic patients.
  • The patient experienced severe gastrointestinal bleeding despite multiple treatments.
  • After using rFVIIa, the patient still suffered from recurrent bleeding and ultimately died.

Takeaway

This study shows that a special medicine called rFVIIa didn't help a patient stop bleeding after a bone marrow transplant, even after trying it many times.

Methodology

Case report detailing the treatment and outcomes of a single patient with severe gastrointestinal bleeding after bone marrow transplantation.

Potential Biases

Publication bias may favor positive outcomes in existing literature.

Limitations

The findings are based on a single case report, which may not be generalizable.

Participant Demographics

45-year old Caucasian male.

Digital Object Identifier (DOI)

10.1186/1477-9560-4-1

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication